Anal and penile condylomas in HIV-negative and HIV-positive men: clinical, histological and virological characteristics correlated to therapeutic outcome.
Clinical, histological and HPV DNA hybridization findings were analyzed for 73 homosexual and 38 heterosexual men attending for anal warts; therapy results were evaluated retrospectively for 76 of these patients. Concurrent anal and penile warts occurred most commonly in the heterosexual men (p < 0.001). While perianal warts were most common in heterosexuals (p < 0.05), intraanal warts were most common in homosexuals (p < 0.001). Altogether 23 homosexual men were HIV-infected; 13 HIV-positive men followed regarding therapeutic outcome were immunologically relatively intact with mean CD4 counts of 524/mm3. Of 136 biopsy specimens 70% revealed benign hyperplasia, 27% AIN I, 2% AIN II and none AIN III. Of ISH positive samples 94% contained HPV 6/11 and 6% HPV 16/18/31/33. Anal warts were cured after an average of 2.5 (mean 1-10) therapy sessions in 64% of heterosexual, in 84% of HIV-negative homosexual and in 62% of HIV-positive homosexual men. The mean number of therapy sessions against anal warts was highest (p < 0.001) and the time for accomplishing cure for anal and penile warts was longest (p < 0.001) in the heterosexual study group.
von Krogh
G
G
Department of Dermatovenereology, Karolinska Hospital, Stockholm, Sweden.
Wikström
A
A
Syrjänen
K
K
Syrjänen
S
S
D000328:Adult; D000368:Aged; D001004:Anus Diseases / Q000473:pathology* / Q000628:therapy / Q000821:virology*; D003218:Condylomata Acuminata / Q000473:pathology* / Q000628:therapy / Q000821:virology*; D004279:DNA, Viral / Q000032:analysis*; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D018451:Homosexuality, Male; D006801:Humans; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000302:isolation & purification*; D010409:Penile Diseases / Q000473:pathology* / Q000628:therapy / Q000821:virology*; D011034:Podophyllotoxin / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
D004279:DNA, Viral; D011034:Podophyllotoxin